Pentarlandir (SNB011) / SyneuRx - LARVOL DELTA

Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China. (PubMed, Eur J Med Chem) - "Small molecule inhibitors (remdesivir, Paxlovid, and molnupiravir) are essential complements to vaccines and play important roles in clinical treatment of SARS-CoV-2...We review development of small molecule anti-SARS-CoV-2 drugs (azvudine [approved by the NMPA of China on July 25, 2022], VV116 [approved by the NMPA of China on January 29, 2023], FB2001, WPV01, pentarlandir, and cepharanthine) in China and summarize their pharmacological activity, potential mechanisms of action, clinical trials and use, and important milestones in their discovery. The role of structural biology in drug development is also reviewed. Future studies should focus on development of diverse second-generation inhibitors with excellent oral bioavailability, superior plasma half-life, increased antiviral activity against SARS-CoV-2 and its variants, high target specificity, minimal side effects, reduced drug-drug interactions, and improved lung histopathology."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Proof of Principle Study to Evaluate the Safety, PK, Viral Shedding and Efficacy of Pentarlandir™ UPPTA for Patients With Early COVID-19 (clinicaltrials.gov) - P2; N=90; Recruiting; Sponsor: SyneuRx International (Taiwan) Corp; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Proof of Principle Study to Evaluate the Safety, PK, Viral Shedding and Efficacy of Pentarlandir™ UPPTA for Patients With Early COVID-19 (clinicaltrials.gov) - P2; N=90; Not yet recruiting; Sponsor: SyneuRx International (Taiwan) Corp

Clinical • New P2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Xinyue Biomedicine: Initiation of human clinical trials of new crown [Google translation] (udn.com) - "Xinyue Biomedical (6575) announced today (12) that it has recently completed the Pentarlandir clinical trial kick-off meeting with Prevail InfoWorks...Xinyue Biomedical said that 90 people were admitted in this clinical plan. The proportion of subjects in the three groups of high-dose, low-dose, and placebo is 1:1:1. It is expected that the first subject will enter the clinic in late June. Interim analysis was carried out when 45 people completed the clinical trial, and 90 people were selected to enter the third phase of the clinical trial after completing the clinical unblindness."

Trial status • Infectious Disease • Novel Coronavirus Disease